Speakers

Edgardo Hernandez (he/him/his) is executive vice president at Eli Lilly and Company and president of manufacturing operations.

Ed served as senior vice president of global parenteral drug product, delivery devices and regional manufacturing from 2018 until 2021. In this role, he was responsible for global parenteral manufacturing, emerging markets manufacturing, drug-product contract manufacturing, packaging, and distribution operations. Ed provided oversight for manufacturing sites in 12 countries across North America, South America, Europe, and Asia; that manufacture the final parenteral product (non-oral) formulations of Lilly medicines.

Previously, Ed was vice president of Fegersheim Operations for Lilly’s manufacturing site located in France. Before that, he served as site head for two other Lilly manufacturing sites: Indianapolis Active Pharmaceutical Ingredient manufacturing from 2014 until 2016, and PR06 in Puerto Rico from 2012 until 2014. Ed joined Lilly in 2005 as an engineering services leader for Lilly del Caribe in Puerto Rico, after working for several years in positions for Pfizer and Pharmacia.

Ed is a native of Puerto Rico and holds bachelor’s and master’s degrees in chemical engineering from the University of Puerto Rico and North Carolina State University, respectively.

Brendan O’Callaghan leads Sanofi’s Manufacturing and Supply organization, a global network of close to 40 internal manufacturing sites, supported by a network of strategic external supply partners. Sanofi’s ambition is to build an Industry leading manufacturing and supply chain capability, based on a future-ready organization and network that will ensure the flawless launch of Sanofi’s rich and diverse late-stage pipeline and the continued, reliable supply of essential, high-quality, affordable and sustainable medicines and vaccines for patients, worldwide. Sanofi will leverage the latest in scientific, digital, technology and workforce solutions to achieve this ambition.

Brendan joined Sanofi in 2015 as Global Head of Biologics, later taking leadership of the integrated Manufacturing and Supply network supporting our Specialty Care portfolio, prior to taking on his current responsibilities in September 2021. He has played a key role in enabling Sanofi’s transformation to a fully integrated BioPharma company and advancing the modernization and digital transformation of our manufacturing teams and network, building capabilities and capacities to support Sanofi’s growth in Biologics, Vaccines and Small Molecule Manufacturing, as highlighted by continued investments into state of the art, digitally advanced and future ready facilities such as the 2020 ISPE Facility of the Year award winning site in Framingham, MA and Sanofi’s agile and industry leading Modulus platforms in Neuville (FR) and Singapore.

Prior to Sanofi, Brendan worked with Merck / MSD, Mallinckrodt and Schering-Plough, where he led Tech Ops organizations of increasing scope and responsibility, across a variety of site and global leadership roles.

Brendan graduated in Chemical Engineering from the University College of Dublin, where he currently serves as an honorary adjunct Professor of Chemical and Biochemical Engineering.

He is married with four sons. A keen sports enthusiast, Brendan is a UEFA qualified soccer coach.

Sanat Chattopadhyay is responsible for the company’s (approx.  $64 billion revenue) worldwide manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines, biologics and animal health products. Merck is known as MSD outside of the U.S. and Canada.

Sanat joined Merck in 2009 as Senior Vice President of Global Vaccines & Sterile Manufacturing Operations, spearheading the transformation of manufacturing and supply chain to grow and globalize its Vaccine business. Under Sanat’s leadership, Merck is currently executing a significant expansion of its biologics and vaccines manufacturing capacity with planned capital investments of more than $20 billion from 2020 through the end of 2024, to reach more patients around the globe.

Before joining Merck, he served as Senior Vice President, Technical Operations & Product Supply, for Wyeth Pharmaceuticals. Previously, he worked at Aventis and its predecessor companies as Senior Vice President, Industrial Operations, having served in many positions with increasing responsibilities for global supply chain, technology and manufacturing sites across North America, Europe and Asia Pacific. Sanat started his career with Hoechst Pharmaceuticals in 1983 and worked in many senior leadership assignments.

Sanat is a graduate in Chemical Engineering and holds a post-graduate degree in Industrial Engineering from India.

Outside of Merck, Sanat is a member of the Board of Directors of Ashland Inc.

Manisha Desai, a seasoned pharmaceutical executive and strategic leader, currently serves as the Senior Vice President of Product Development within Global Product Development and Supply (GPS) at Bristol Myers Squibb (BMS).  Throughout her 25-plus-year career at BMS, Manisha has developed extensive expertise in the biopharma industry, with a focus on end-to-end CMC development. This includes the design & development, scale-up, and technology transfer for both oral and parenteral drug products for BMS’s small and large molecule portfolio, as well as combination products, to manufacturing sites. In addition to her technical expertise, Manisha has excelled in developing and executing organizational strategy, leading strategic partnerships, building high-performing teams, managing large global organizations, shaping organizational culture, and guiding teams through change.

Manisha earned her bachelor’s and Masters degree in Pharmaceutical Sciences from the University of Mumbai, India; her Ph.D. in Pharmaceutical Sciences from the University of Michigan; and her MBA from the NYU Stern School of Business.

Outside of work, Manisha enjoys spending time with her family and friends, traveling, engaging in charity work, and watching shows on Broadway.

Stephen Hill is the Chief Operating Officer at Lyell. He is responsible for research and end-to-end development and supply of cell therapies to support Lyell’s clinical and commercial aspirations.

Hill was formerly Head of Biologic Operations at AstraZeneca where he was responsible for end-to-end supply of the commercial and late-stage clinical portfolio for Biologics that included oversight of six manufacturing sites across the US and Europe and five commercial products.

As Vice President Operations, Site Head at the AstraZeneca Frederick Manufacturing Center, Hill was responsible for the largest biologics manufacturing facility within the company’s global network. The site consists of a licensed, large-scale cell culture facility and recently commissioned small-scale facility.

Prior to AstraZeneca Hill served as Vice President Bulk Manufacturing at Amgen’s Puerto Rico facility and as Executive Director leading commercial formulation and filling and commercial drug substance operations.

Hill also served prior roles as Executive Director, Manufacturing Technologies leading manufacturing global networks and as Executive Director, Plant Manager leading clinical drug substance operations. In his corporate role he led manufacturing of the future, operations strategy, high reliability performance and manufacturing global network initiatives. In his plant manager role he was an effective change agent driving productivity improvement to deliver multiple pipeline new product introductions annually.

Hill joined Amgen from ICOS Corporation where he executed GMP clinical plant start-up and led manufacturing, ultimately transitioning the operation into a contract manufacturing business. Hill started his career at Immunex Corporation as an operator manufacturing Enbrel.

Hill holds a Master in Business Administration (MBA) and Bachelor’s in Microbiology (BS) and Political Science (BA) from the University of Washington.

Aine’s career in the biomanufacturing sector spans roles in the UK, Ireland, and the US, with a strong focus on developing innovative solutions to expedite the delivery of medicines to patients. Aine Hanly has recently rejoined Amgen as Vice President, Quality. In this role, Aine will lead a global team accountable for all aspects of quality oversight for Amgen’s products, from early product and process design to manufacturing and product supply to ensure that quality standards are met and in compliance with applicable regulatory requirements.

Prior to her return to Amgen, Aine spent the past 4 years with Vir Biotechnology, an immunology-based biopharmaceutical company developing medicines for infectious diseases and other serious conditions. Aine was the Chief Technology Officer (CTO) and EVP Technical Operations, leading the company’s technical operations function, which included responsibility for end-to end GxP Quality and Data Strategy.

Prior to Vir, in her almost decade-long tenure at Amgen, Aine led teams across several Amgen sites (ACO, AML, AMA and ATO) including oversight of clinical manufacturing and clinical supply (MCS). Her leadership roles in Process development supported the commercialization of Amgen’s pipeline products and technical support for ongoing manufacturing operations. As the site head at Amgen’s Cambridge facility, Aine also led the site’s transformation and staff expansion.

Prior to joining Amgen in 2012, Aine held roles of increasing responsibility in Pfizer (formerly Wyeth) Process Development, Product Supply and Quality including site head of Quality for Pfizer’s Grange Castle Manufacturing site in Ireland.

Aine earned her bachelor’s degree in biological chemistry and her Ph.D. in physical organic chemistry from the University of Ulster in Northern Ireland. She completed her post-doctoral fellowship at Creighton University School of Medicine before joining Yale University and CuraGen Corporation as a lead scientist, where she focused on gene isolation and validation using various molecular biology techniques.

Dr. Pat Yang is one of the most accomplished biotech manufacturing executives and technical operations leaders in the industry.

From 2017 to 2019, Pat was executive vice president at Juno Therapeutics, a leading CAR-T biotech company (now part of BMS) based in Seattle.

Previously, from 2009 to 2013, Pat was Executive Vice President and Global Head of Technical Operations at F. Hoffman-La Roche based in Basel, Switzerland. In this role, he was responsible for Roche’s biopharma process research and development, analytical sciences, engineering, quality, technical regulatory, supply chain and all manufacturing plants with approximately 15,000 employees around the world. From 2003 to 2009, Pat was Executive Vice President of Product Operations at Genentech. He assumed his role as Global Head of the combined technical operations of Roche and Genentech upon the acquisition of Genentech by Roche in 2009.

Before Genentech, Pat worked for 11 years at Merck & Company from 1992 to 2003, based in New Jersey, in various leadership positions including vice president of Asia Pacific Operations and vice president of Global Supply Chain Management. Prior to joining Merck in 1992, Pat spent 12 years at General Electric, serving in research, engineering, technology, and manufacturing leadership roles with increasing scope of responsibilities.

Pat holds a Bachelor of Science from the National Chiaotung University in Taiwan, a Master of Science from the University of Cincinnati, and a Ph.D. in engineering from Ohio State University.

Pat is a member of the Board of Directors of three public companies, Amyris, Codexis and PharmaEssentia. In addition, he is on the board of several private companies, including Acepodia, AltruBio, Antheia and Sana Biotechnology.

Pascal leads Russell Reynolds’ operations in New York and Canada. He works closely with our healthcare clients around the globe, advising them on their talent strategy, including leadership assessment, succession planning, and the recruitment of directors, CEOs, and other senior executives.

Within the healthcare industry, Pascal specializes in biotech and pharma technical operations, including process development, manufacturing, quality, engineering, and supply chain leadership.

Pascal received his Bachelor of Engineering Physics degree from the Royal Military College of Canada and trained as an aerospace engineer with the Royal Canadian Air Force. He also earned master’s and doctorate degrees in business administration from Athabasca University in Canada, where he focused his research and dissertation on CEO succession. Pascal speaks fluent French and English.

Craig Beasley is the Chief Technical Officer at BlueRock Therapeutics. Prior to joining BlueRock, Craig was the Vice President, Cell Therapy Supply Chain at BMS, where he oversaw supply chain for BMS’s clinical and commercial stage cell therapy assets. Previously, Craig was Head of Manufacturing and Supply Chain at Juno Therapeutics and Vice President of Next Generation Manufacturing at Biogen. Prior to working in biotechnology, Craig worked for Union Carbide in process development. Craig holds a B.S. in Chemical Engineering from Purdue University.

Angela Jung specializes in recruiting transformational technology executives for global Fortune 500, private equity, venture capital, and growth-stage firms.

Based in New York, Angela is a leader in our global cybersecurity team and a member of our Technology Practice. She excels at recruiting Chief Information Officers, Chief Information Security Officers, Chief Technology Officers, Technology Operating Partners, and board directors. During her career, Angela has proven herself as a trusted advisor, delivering tailored leadership solutions to ensure her clients succeed in a rapidly evolving technology landscape.

Prior to joining Russell Reynolds Associates, Angela served in the US Army as a Military Intelligence Officer and was one of the first women assigned to an Infantry Battalion. She rose through the ranks from Lieutenant to Captain and held multiple leadership positions across information security, operational security, and anti-terrorism in support of a Brigade Combat Team’s operations in the Pacific Theater.
Angela received her BS in biology from the University of Miami and her MBA from Columbia Business School. She also speaks fluent Korean.

L.-C. Campeau obtained his Ph. D. degree in 2007 with the late Professor Keith Fagnou at the University of Ottawa in Canada. He first joined Merck Research Laboratories at Merck-Frosst in Montreal in 2007 where he was recognized for key contributions to the discovery of Doravirine (MK-1439) a next generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. In 2010, he moved from Quebec to New Jersey, where he has served in roles of increasing responsibility. L.-C. is currently Associate Vice President and the Head of Small Molecule Process Research and Development. Over his tenure at Merck, L.-C. and his team have made important contributions to >60 clinical candidates and 7 commercial products. Under his leadership, his organization was recognized with 5 EPA Green Chemistry Challenge Award and 2 Heroes of Chemistry Award. His passion for scientific excellence is exemplified by >85 publications and patents, and >95 invited lectures worldwide. L.-C. was elected Fellow of the Royal Society of Canada in 2022.